Patient-specific neoantigenic peptide presented by autologous human leukocyte antigen (HLA) (Neoantigen-HLA complex)

Patient-specific neoantigenic peptides presented by autologous human leukocyte antigen (HLA) are unique protein fragments resulting from somatic mutations within a patient's tumor cells (Schumacher & Schreiber, 2015, Science). Unlike shared tumor-associated antigens, these neoantigens are entirely absent from healthy tissues, providing a high degree of tumor specificity and reducing the risk of autoimmune cross-reactivity (Blass & Ott, 2021, Nature Reviews Clinical Oncology). The therapeutic targeting of these complexes involves identifying mutations via whole-exome sequencing and using bioinformatics to predict which mutated peptides will bind most effectively to the patient's specific HLA alleles (Ott et al., 2017, Nature). Once identified, these neoantigens are used to develop personalized vaccines, such as mRNA or peptide-based platforms, or to engineer T-cell receptor (TCR) therapies (Sahin et al., 2017, Nature). These therapies are designed to trigger a robust, cytotoxic T-cell response that selectively eliminates cells expressing the target neoantigen-HLA complex. This approach is a cornerstone of precision oncology, aiming to overcome the limitations of traditional immunotherapies by focusing the immune system on the most relevant and immunogenic targets within a specific patient's cancer (Hu et al., 2021, Nature Reviews Immunology). However, challenges remain, including the potential for tumor escape through HLA downregulation or loss of the target mutation (Garrido et al., 2016, Cancer Immunology, Immunotherapy). Additionally, the manufacturing process for these personalized therapies is complex and time-sensitive, requiring rapid turnaround to benefit patients with advanced disease.

Other names

Tumor-specific neoantigenNeoepitopeHLA-restricted neoantigenPersonalized neoantigenTSA-HLA complex

Induction of a de novo or expanded T-cell response against tumor-specific mutations, leading to selective destruction of malignant cells while sparing healthy tissue (Schumacher & Schreiber, 2015, Science).